eli lilly glp-1 drug Lilly's Trulicity joins pay-for-performance trend with Harvard Pilgrim deal Orforglipron: Eli Lilly's New Oral
Description
doi: 10.1161/HYPERTENSIONAHA.113.00588 96 GaspariTLiuHWelungodaIHuYWiddopREKnudsenLBet al
Some people with underlying motility issues tolerate semaglutide better than tirzepatide, making the switch potentially beneficial
Neuen BL, Heerspink HJL, Vart P, et al
They should then start the lowest dose of the alternative once-weekly GLP-1 receptor agonist and consider a lower maintenance dose
What Should You Consider: Safety: Compounded medications are not FDA-approved
[DOI] [PMC free article] [PubMed] [Google Scholar] 36.Lucey M, Pickford P, Bitsi S, et al
